University Of Tasmania
Khalafallah et al MJHID 2011.pdf (2.31 MB)
Download file

Quality of Life Assessment in Multiple Myeloma Patients Undergoing Dose-Reduced Tandem Autologous Stem Cell Transplantation

Download (2.31 MB)
journal contribution
posted on 2023-05-17, 10:15 authored by Alhossain Khalafallah, McDonnell, K, Dawar, HU, Iain RobertsonIain Robertson, Woods, D
Few studies exist that consider health-related quality of life (HR-QoL) in patients with multiple myeloma (MM) undergoing tandem autologous stem cell transplantation (TASCT). Eighteen patients with advanced MM who underwent dose-modified TASCT were enrolled in this study between March 2006 and March 2008. Patients <60 year old (10) received conditioning with melphalan 140 mg/m(2) and patients who were ¡Ý60 years (8) received 100 mg/m(2). The median age was 57.5 years (range 35-69). We conducted the European Organization of Research and Treatment of Cancer (EORTC) QLQ-C30 and the QLQ-MY24 questionnaires via interviews at presentation, after each ASCT and thereafter every 3 months for 24 months. Mean global health measure improved from 3.44 before transplant to 4.50 (1=very poor, 7=excellent) at the second and subsequent follow-up visits (P<0.001) and the mean global quality of life score improved from 3.61 to 4.71 (P<0.001). Pain symptoms were reduced (P=0.001), and physical functioning improved (P<0.001) throughout the period of post-transplant follow-up. Our study showed that dose-reduced TASCT is well tolerated with low toxicity albeit the transient reduction in QoL during both transplants. Post-transplant follow-up showed significant improvement in overall HR-QoL that reflects positively on the overall disease-outcome. Furthermore, a sole focus on patient-survival does not adequately provide indication regarding the tolerability and effectiveness of a proposed treatment on the patient's perceived quality of life. As clinicians, our primary concern should be toward patient-welfare as well as survival. Therefore, we should employ the tools of QoL in conjunction with overall survival in order to deliver the best possible patient outcomes. The EORTC-QLQ-MY24 is a practical tool in measuring QoL in myeloma patients.


Publication title

Mediterranean Journal of Hematology and Infectious Diseases

Article number









School of Health Sciences


Universita Cattolica del Sacro Cuore Istituto di Ematologia

Place of publication


Rights statement

Licensed under Creative Commons Attribution 2.0 Generic (CC BY 2.0)

Repository Status

  • Open

Socio-economic Objectives

Diagnosis of human diseases and conditions

Usage metrics